Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life

O. Henry, J. Brzostek, H. Czajka, G. Leviniene, O. Reshetko, R. Gasparini, P. Pazdiora, D. Plesca, MG. Desole, R. Kevalas, G. Gabutti, M. Povey, B. Innis,

. 2018 ; 36 (3) : 381-387. [pub] 20171207

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033480
E-zdroje Online Plný text

NLK ProQuest Central od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-01-01 do Před 2 měsíci
Family Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest) od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest) od 2002-01-01 do Před 2 měsíci

Odkazy

PubMed 29224964
DOI 10.1016/j.vaccine.2017.11.081
Knihovny.cz E-zdroje

BACKGROUND: This phase III B follow-up of an initial multicenter study (NCT00226499) will evaluate the ten-year efficacy of two doses of the combined measles-mumps-rubella-varicella vaccine (MMRV) and one dose of the live attenuated varicella vaccine (V) versus a measles-mumps-rubella control group (MMR) for the prevention of clinical varicella disease. Here we present efficacy results for six years post-vaccination. METHODS: In phase A of the study, healthy children aged 12-22 months from ten European countries were randomized (3:3:1) and received either two doses of MMRV, or one dose of combined MMR and one dose of monovalent varicella vaccine (MMR+V), or two doses of the MMR vaccine (control), 42 days apart. Vaccine efficacy against all and against moderate or severe varicella (confirmed by detection of viral DNA or epidemiological link) was assessed from six weeks up to six years post-dose 2 for the MMRV and MMR+V groups, and was calculated with 95% confidence intervals (CI). The severity of varicella was calculated using the modified Vázquez scale (mild ≤ 7; moderately severe = 8-15; severe ≥ 16). Herpes zoster cases were also recorded. RESULTS: 5289 children (MMRV = 2279, mean age = 14.2, standard deviation [SD] = 2.5; MMR+V = 2266, mean age = 14.2, SD = 2.4; MMR = 744, mean age = 14.2, SD = 2.5 months) were included in the efficacy cohort. 815 varicella cases were confirmed. Efficacy of two doses of MMRV against all and against moderate or severe varicella was 95.0% (95% CI: 93.6-96.2) and 99.0% (95% CI: 97.7-99.6), respectively. Efficacy of one dose of varicella vaccine against all and against moderate or severe varicella was 67.0% (95% CI: 61.8-71.4) and 90.3% (95% CI: 86.9-92.8), respectively. There were four confirmed herpes zoster cases (MMR+V = 2, MMR = 2), all were mild and three tested positive for the wild-type virus. CONCLUSIONS: Two doses of the MMRV vaccine and one dose of the varicella vaccine remain efficacious through six years post-vaccination.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033480
003      
CZ-PrNML
005      
20181012094120.0
007      
ta
008      
181008s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vaccine.2017.11.081 $2 doi
035    __
$a (PubMed)29224964
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Henry, Ouzama $u Vaccine Discovery and Development, GSK, Philadelphia, United States. Electronic address: ouzama.n.henry@gsk.com.
245    10
$a One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life / $c O. Henry, J. Brzostek, H. Czajka, G. Leviniene, O. Reshetko, R. Gasparini, P. Pazdiora, D. Plesca, MG. Desole, R. Kevalas, G. Gabutti, M. Povey, B. Innis,
520    9_
$a BACKGROUND: This phase III B follow-up of an initial multicenter study (NCT00226499) will evaluate the ten-year efficacy of two doses of the combined measles-mumps-rubella-varicella vaccine (MMRV) and one dose of the live attenuated varicella vaccine (V) versus a measles-mumps-rubella control group (MMR) for the prevention of clinical varicella disease. Here we present efficacy results for six years post-vaccination. METHODS: In phase A of the study, healthy children aged 12-22 months from ten European countries were randomized (3:3:1) and received either two doses of MMRV, or one dose of combined MMR and one dose of monovalent varicella vaccine (MMR+V), or two doses of the MMR vaccine (control), 42 days apart. Vaccine efficacy against all and against moderate or severe varicella (confirmed by detection of viral DNA or epidemiological link) was assessed from six weeks up to six years post-dose 2 for the MMRV and MMR+V groups, and was calculated with 95% confidence intervals (CI). The severity of varicella was calculated using the modified Vázquez scale (mild ≤ 7; moderately severe = 8-15; severe ≥ 16). Herpes zoster cases were also recorded. RESULTS: 5289 children (MMRV = 2279, mean age = 14.2, standard deviation [SD] = 2.5; MMR+V = 2266, mean age = 14.2, SD = 2.4; MMR = 744, mean age = 14.2, SD = 2.5 months) were included in the efficacy cohort. 815 varicella cases were confirmed. Efficacy of two doses of MMRV against all and against moderate or severe varicella was 95.0% (95% CI: 93.6-96.2) and 99.0% (95% CI: 97.7-99.6), respectively. Efficacy of one dose of varicella vaccine against all and against moderate or severe varicella was 67.0% (95% CI: 61.8-71.4) and 90.3% (95% CI: 86.9-92.8), respectively. There were four confirmed herpes zoster cases (MMR+V = 2, MMR = 2), all were mild and three tested positive for the wild-type virus. CONCLUSIONS: Two doses of the MMRV vaccine and one dose of the varicella vaccine remain efficacious through six years post-vaccination.
650    _2
$a protilátky virové $x krev $7 D000914
650    _2
$a plané neštovice $x patologie $x prevence a kontrola $7 D002644
650    _2
$a vakcína proti planým neštovicím $x aplikace a dávkování $x imunologie $7 D019433
650    _2
$a Evropa $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a herpes zoster $x patologie $x prevence a kontrola $7 D006562
650    _2
$a lidé $7 D006801
650    12
$a očkovací schéma $7 D007115
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a atenuované vakcíny $x aplikace a dávkování $x imunologie $7 D014613
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Brzostek, Jerzy $u Poradnia Chorób Zakaźnych ZOZ Dębica, Dębica, Poland. Electronic address: jerzy_br@poczta.onet.pl.
700    1_
$a Czajka, Hanna $u Infectious Diseases Outpatient Clinic, The St. Luis Provincial Specialist Children's Hospital, Cracow, Poland. Electronic address: hanna.czajka@onet.pl.
700    1_
$a Leviniene, Giedra $u Pediatric Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania. Electronic address: giedralev@gmail.com.
700    1_
$a Reshetko, Olga $u Pharmacology, Saratov Medical University, Saratov, Russia. Electronic address: reshetko@yandex.ru.
700    1_
$a Gasparini, Roberto $u Department of Health Sciences, Genoa University, Genoa, Italy. Electronic address: gasparini@unige.it.
700    1_
$a Pazdiora, Petr $u Department of Epidemiology, Medical Faculty Pilsen of Charles University, Czech Republic. Electronic address: PAZDIORA@fnplzen.cz.
700    1_
$a Plesca, Doina $u Pediatrics, University of Medicine and Pharmacy, Bucharest, Romania. Electronic address: doinaplesca@yahoo.com.
700    1_
$a Desole, Maria Giuseppina $u Servizio di Igiene Pubblica, ASL Sassari, Italy. Electronic address: madesole@aslsassari.it.
700    1_
$a Kevalas, Rimantas $u Pediatric Clinic, Lithuanian University of Health Sciences, Kaunas, Lithuania. Electronic address: rimantas.kevalas@kaunoklinikos.lt.
700    1_
$a Gabutti, Giovanni $u Department of Medical Sciences, University of Ferrara, Ferrara, Italy. Electronic address: giovanni.gabutti@unife.it.
700    1_
$a Povey, Michael $u Biostatistics, GSK, Wavre, Belgium. Electronic address: michael.x.povey@gsk.com.
700    1_
$a Innis, Bruce $u Vaccine Discovery and Development, GSK, Philadelphia, United States. Electronic address: innisb00@gmail.com.
773    0_
$w MED00004631 $t Vaccine $x 1873-2518 $g Roč. 36, č. 3 (2018), s. 381-387
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29224964 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181012094612 $b ABA008
999    __
$a ok $b bmc $g 1339472 $s 1030474
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 36 $c 3 $d 381-387 $e 20171207 $i 1873-2518 $m Vaccine $n Vaccine $x MED00004631
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace